Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Majka, Marcin  [Clear All Filters]
2013
Wędrychowicz A, Sztefko K, Majka M, Ratajczak MZ. [The role of Insulin-like Growth Factor 1, Receptor Activator for Nuclear Factor κB ligand - Osteoprotegerin system, Interleukin 6 and 1β in post-transplantation bone metabolic disease in childhood]. Endokrynol Pol. 2013;64(4):248-54.
2014
Jarocha D, Milczarek O, Kawecki Z, Wendrychowicz A, Kwiatkowski S, Majka M. Preliminary Study of Autologous Bone Marrow Nucleated Cells Transplantation in Children With Spinal Cord Injury. Stem Cells Transl Med. 2014.
2015
Skrzypek K, Kusienicka A, Szewczyk B, Adamus T, Lukasiewicz E, Miekus K, Majka M. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression. Oncotarget. 2015.
Musialek P, Mazurek A, Jarocha D, Tekieli L, Szot W, Kostkiewicz M, R Banys P, Urbanczyk M, Kadzielski A, Trystula M, et al. Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf 'unlimited' therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study. Postepy Kardiol Interwencyjnej. 2015;11(2):100-7.
2019
Kot M, Musiał-Wysocka A, Lasota M, Ulman A, Majka M. Secretion, migration and adhesion as key processes in the therapeutic activity of mesenchymal stem cells. Acta Biochim Pol. 2019.
2024
Milczarek O, Jarocha D, Starowicz-Filip A, Kasprzycki M, Kijowski J, Mordel A, Kwiatkowski S, Majka M. Bone Marrow Nucleated Cells and Bone Marrow-Derived CD271+ Mesenchymal Stem Cell in Treatment of Encephalopathy and Drug-Resistant Epilepsy. Stem Cell Rev Rep. 2024.